WallStreetZenWallStreetZen

NASDAQ: HYPR
Hyperfine Inc Stock

Overview
ForecastEarningsRevenueDividendOwnership
$1.20-0.02 (-1.64%)
Updated Jan 16, 2026
HYPR Price
$1.20
Fair Value Price
N/A
Market Cap
$116.60M
52 Week Low
$0.53
52 Week High
$2.22
P/E
-2.31x
P/B
4.34x
P/S
10.82x
PEG
N/A
Dividend Yield
N/A
Revenue
$10.59M
Earnings
-$40.05M
Gross Margin
46.1%
Operating Margin
-378.17%
Profit Margin
-378.2%
Debt to Equity
0.55
Operating Cash Flow
-$31M
Beta
1.23
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

HYPR Overview

Hyperfine, Inc., a medical device company, created Swoop, a portable MRI system that produces images at a lower magnetic field strength, allowing clinicians to quickly scan, diagnose and treat patients in various clinical settings. Swoop can be wheeled directly to the patient's bedside, plugged into a standard electrical wall outlet, and controlled by an iPad. The company was incorporated in 2014 and is based in Guilford, CT.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine HYPR's potential to beat the market

CHold
  • Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
View All “A” Zen Rated Stocks
→

Zen Rating Component Grades

D
Value
B
Growth
C
Momentum
C
Sentiment
C
Safety
F
Financials
D
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Medical Device

Industry Rating
C
HYPR
Ranked#60 of 100

Top Ranked Stocks in Industry

Name / TickerPriceZen Rating
Varex Imaging (VREX)
$13.79A
Tactile Systems Technology (TCMD)
$30.46A
Bioventus (BVS)
$7.93A
View Top Medical Device Stocks

Be the first to know about important HYPR news, forecast changes, insider trades & much more!

HYPR News

Overview

Due Diligence Score

–
Industry Average (26)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how HYPR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

HYPR is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
HYPR is poor value based on its book value relative to its share price (4.34x), compared to the US Medical Devices industry average (3.86x)
P/B vs Industry Valuation
HYPR is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more HYPR due diligence checks available for Premium users.

Valuation

HYPR price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-2.31x
Industry
23.65x
Market
46.6x

HYPR price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
4.34x
Industry
3.86x
HYPR is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

HYPR's financial health

Profit margin

Revenue
$3.4M
Net Income
-$11.0M
Profit Margin
-320.6%
HYPR's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
HYPR's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$41.5M
Liabilities
$14.6M
Debt to equity
0.55
HYPR's short-term assets ($36.90M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
HYPR's short-term assets ($36.90M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
HYPR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$5.6M
Investing
-$130.0k
Financing
$2.2M
HYPR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

HYPR vs Medical Device Stocks

TickerZen RatingMarket Cap1d %P/EP/B
HYPRC$116.60M-1.64%-2.31x4.34x
RCELF$118.92M+12.72%-2.15x-17.84x
PMIC$120.87M-3.53%N/A15.17x
ANIKB$134.26M-2.31%-4.10x0.91x
MXCTD$134.41M-2.33%-2.86x0.75x
View Top Medical Device Stocks

Hyperfine Stock FAQ

What is Hyperfine's quote symbol?

(NASDAQ: HYPR) Hyperfine trades on the NASDAQ under the ticker symbol HYPR. Hyperfine stock quotes can also be displayed as NASDAQ: HYPR.

If you're new to stock investing, here's how to buy Hyperfine stock.

What is the 52 week high and low for Hyperfine (NASDAQ: HYPR)?

(NASDAQ: HYPR) Hyperfine's 52-week high was $2.22, and its 52-week low was $0.53. It is currently -45.95% from its 52-week high and 125.14% from its 52-week low.

How much is Hyperfine stock worth today?

(NASDAQ: HYPR) Hyperfine currently has 97,168,657 outstanding shares. With Hyperfine stock trading at $1.20 per share, the total value of Hyperfine stock (market capitalization) is $116.60M.

Hyperfine stock was originally listed at a price of $10.01 in Jan 27, 2021. If you had invested in Hyperfine stock at $10.01, your return over the last 4 years would have been -88.01%, for an annualized return of -41.16% (not including any dividends or dividend reinvestments).

How much is Hyperfine's stock price per share?

(NASDAQ: HYPR) Hyperfine stock price per share is $1.20 today (as of Jan 16, 2026).

What is Hyperfine's Market Cap?

(NASDAQ: HYPR) Hyperfine's market cap is $116.60M, as of Jan 18, 2026.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Hyperfine's market cap is calculated by multiplying HYPR's current stock price of $1.20 by HYPR's total outstanding shares of 97,168,657.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.